Courriel : bd@sidmexinovia.com
Téléphone : +918866862020
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Empasov 25mg Tablet
Manufacturer/Marketed By : CIPLA LTD
$1.50 $1.36
Empasov 25mg Tablet is an oral medication belonging to the pharmacological class of sodium-glucose co-transporter-2 (SGLT2) inhibitors. It is primarily used for managing type 2 diabetes mellitus by improving glycemic...
Collapsible text is perfect for longer content like paragraphs and descriptions. It's a great way to give people more information while keeping your layout clean. Link your text to anything, including an external website or a different page. You can set your text box to expand and collapse when people click, so they can read more or less info.
EMPAGLIFLOZIN
Active Pharmaceutical Ingredient
Empasov 25mg Tablet
1,50 $US
1,36 $US
Empasov 25mg Tablet is an oral medication belonging to the pharmacological class of sodium-glucose co-transporter-2 (SGLT2) inhibitors. It is primarily used for managing type 2 diabetes mellitus by improving glycemic control. Additionally, it may help reduce the risk of cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Empasov 25mg Tablet is available in tablet form and is typically administered once daily, with or without food. Empasov 25mg Tablet works by blocking SGLT2 proteins in the kidneys, preventing glucose reabsorption and promoting glucose excretion through urine. While Empasov 25mg Tablet is generally considered safe for most individuals, but caution should be exercised in patients with renal impairment, those with a history of diabetic ketoacidosis, or individuals with hypersensitivity to the active constituent. It is contraindicated during pregnancy and breastfeeding unless specifically advised by a healthcare provider.
Active Pharmaceutical Ingredient
Uses
• Management of type 2 diabetes mellitus to improve glycemic control.
• Reduction of cardiovascular risk in adults with type 2 diabetes and established cardiovascular disease.
• Potential benefits in managing heart failure and chronic kidney disease (as recommended by healthcare professionals).
Benefits
Empasov 25mg Tablet works by inhibiting the SGLT2 proteins located in the proximal renal tubules of the kidneys. By blocking these proteins, it reduces glucose reabsorption and promotes the excretion of excess glucose through urine. This mechanism helps lower blood sugar levels effectively and provides cardiovascular and renal protective benefits. Additionally, Empasov 25mg Tablet may help reduce body weight and blood pressure as secondary effects, which are beneficial for patients with type 2 diabetes.
Side Effects
Common Side Effects
Most Common Side Effects
• Severe hypoglycemia (when combined with insulin or insulin secretagogues)
• Ketoacidosis (rare but serious)
• Acute kidney injury
• Severe allergic reactions (rash, itching, swelling)
Common Side Effects
• Increased urination
• Thirst
• Dizziness
• Genital yeast infections (especially in women)
• Urinary tract infections
How To Use
Empasov 25mg Tablet is available in tablet form, typically taken once daily, with or without food. Swallow the tablet whole with water. Adhere to the prescribed dosage as instructed by your healthcare provider. Do not alter or discontinue the medication without professional guidance.
Safety Advice
• Breast Feeding: It is unknown whether Empasov 25mg Tablet passes into breast milk. Avoid use or consult a healthcare provider for advice.
• Alcohol: Consumption of alcohol may increase the risk of dehydration and affect blood sugar control.
• Liver: Patients with severe liver impairment should use Empasov 25mg Tablet with caution and under medical supervision.
• Lungs: Empasov 25mg Tablet does not have known adverse effects on lung function.
• Driving: Patients experiencing dizziness or fatigue should avoid driving until symptoms subside.
• Pregnancy: Empasov 25mg Tablet should be avoided during pregnancy unless prescribed by a healthcare provider. Limited data suggests potential harm to the developing fetus.
Disclaimer
Sidmex Inovia s'efforce de fournir des informations exactes et fiables. Cependant, l'ensemble du contenu de ce site web, y compris les descriptions et compositions des produits, est fourni à titre informatif uniquement et ne saurait se substituer à un avis, un diagnostic ou un traitement médical professionnel.
Il est conseillé aux utilisateurs de consulter un professionnel de santé qualifié avant toute décision médicale. Les informations fournies ne doivent pas être utilisées pour l'autodiagnostic ou l'automédication.
Tous les produits présentés sont exclusivement destinés aux professionnels (B2B) et aux demandes de renseignements en gros. Sidmex Inovia ne promeut pas la consommation directe par les particuliers et vise à soutenir, et non à remplacer, la relation entre le professionnel de santé et le patient.
Les noms de produits, marques et logos appartiennent à leurs propriétaires respectifs et leur utilisation n'implique aucune affiliation ni aucun parrainage. Sidmex Inovia décline toute responsabilité quant aux conséquences découlant de l'utilisation des informations fournies sur ce site web.